LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $1,028,456.11 in Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 690,239 shares of the firm’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $1.49, for a total transaction of $1,028,456.11. Following the sale, the insider owned 4,128,912 shares of the company’s stock, valued at approximately $6,152,078.88. This represents a 14.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Friday, October 17th, Gilde Healthcare Cooperatieve sold 1,181,131 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.47, for a total transaction of $1,736,262.57.
• On Tuesday, October 14th, Gilde Healthcare Cooperatieve sold 227,341 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.51, for a total transaction of $343,284.91.
• On Monday, October 13th, Gilde Healthcare Cooperatieve sold 47,686 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.54, for a total value of $73,436.44.
• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $77,296.95.
• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.56, for a total value of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.57, for a total value of $45,457.78.

LAVA Therapeutics Price Performance

LVTX stock opened at $1.63 on Thursday. LAVA Therapeutics N.V. has a fifty-two week low of $0.85 and a fifty-two week high of $2.09. The stock has a market capitalization of $42.89 million, a price-to-earnings ratio of -1.55 and a beta of 0.50. The business’s fifty day moving average price is $1.55 and its two-hundred day moving average price is $1.40.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Research analysts expect that LAVA Therapeutics N.V. will post -1.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LAVA Therapeutics in a research note on Wednesday, October 8th. HC Wainwright cut their target price on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating for the company in a research report on Tuesday, August 5th. Finally, Jefferies Financial Group lowered LAVA Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $3.00 to $1.50 in a report on Tuesday, August 5th. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $2.69.

Hedge Funds Weigh In On LAVA Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LVTX. BML Capital Management LLC acquired a new position in shares of LAVA Therapeutics during the 1st quarter worth $2,490,000. Rangeley Capital LLC bought a new position in LAVA Therapeutics in the second quarter valued at about $36,000. XTX Topco Ltd acquired a new position in LAVA Therapeutics during the first quarter worth about $31,000. Finally, Lepercq De Neuflize Asset Management LLC acquired a new stake in shares of LAVA Therapeutics in the 1st quarter valued at approximately $29,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.